Table 3.
Pharmacokinetic parameters at steady state for a model sertraline normal metabolizer with concurrent cannabinoid use assuming a 25% reduction in clearance.
| THC or Low-Dose CBD | ||
|---|---|---|
| − | + | |
| t1/2 (h) | 22.1 | 29.5 |
| AUC24, 50 mg q.d. (days ng/mL) | 18.0 | 23.7 |
| Cmax, 50 mg q.d. (ng/mL) | 21.9 | 27.4 |
| AUC24, 100 mg q.d. (days ng/mL) | 36.1 | 47.9 |
| Cmax, 100 mg q.d. (ng/mL) | 44.0 | 55.3 |
| AUC24, 150 mg q.d. (days ng/mL) | 54.2 | 72.1 |
| Cmax, 150 mg q.d. (ng/mL) | 66.0 | 83.2 |
| AUC24, 200mg q.d. (days ng/mL) | 72.3 | 98.45 |
| Cmax, 200 mg q.d. (ng/mL) | 88.0 | 111.7 |